More about
Severe Respiratory Syncytial Virus Disease
CME
Video
Pediatric RSV Prevention: Advances in Disease State, Immunization, and Interprofessional Care
This activity is supported by an educational grant from Sanofi US.
CME
Video
Updates in Preventing Pediatric RSV: Rapid Response From IDWeek
This activity is supported by an educational grant from Sanofi US.
News
May 13, 2024
2 min read
Save
Palivizumab cost-effective for prevention of severe RSV in infants
Palivizumab was consistently found to be cost-effective as prophylaxis for respiratory syncytial virus disease among neonates on four continents, according to a study presented at the Pediatric Academic Societies Meeting.